By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported flat year-over-year second-quarter revenues and a slight increase in its net loss, as the firm continues studies of its stool-based DNA test for colorectal cancer.

The Madison, Wis.-based molecular diagnostics firm brought in a total of $1.3 million in revenues for the three-month period ended June 30, roughly flat with the second quarter of 2009. Almost the entirety of revenues came from license fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.